You are here

Oyster Point

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01

BioSpace

dry eye disease

Flag link:

Amid lab space scarcity, a life sciences complex to rise in South San Francisco hub

Amid lab space scarcity, a life sciences complex to rise in South San Francisco hub

Endpoints

Flag link:

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

BioCentury

dry eye disease

Flag link:

AbbVie hatches plans for a major new R&D hub close to its partners in Bay Area's buzzy Oyster Point

AbbVie hatches plans for a major new R&D hub close to its partners in Bay Area's buzzy Oyster Point

Endpoints

Flag link:

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

BioCentury

dry eye disease

clinical trials

Flag link:

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Hoping to shake Allergan/Shire’s dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug

Endpoints

dry eye disease

Flag link: